LRRK2 ANTIBODY
Source Reactivity Background References- Product Name
- LRRK2 ANTIBODY
- Chemical Name
- LRRK2 ANTIBODY
- Synonyms
- LRRK2 ANTIBODY;Mouse Monoclonal LRRK2 Antibody
- CBNumber
- CB14727333
- Formula Weight
- 0
- MOL File
- Mol file
N-Bromosuccinimide Price
- Product number
- orb500678
- Product name
- LRRK2 antibody
- Purity
- Affinity purified by Protein A
- Packaging
- 100μg
- Price
- $421.6
- Updated
- 2021/12/16
- Product number
- orb18949
- Product name
- LRRK2 antibody
- Purity
- Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
- Packaging
- 100μg
- Price
- $499.8
- Updated
- 2021/12/16
- Product number
- orb500678
- Product name
- LRRK2 antibody
- Purity
- Affinity purified by Protein A
- Packaging
- 200μg
- Price
- $673.2
- Updated
- 2021/12/16
- Product number
- orb150586
- Product name
- LRRK2 antibody
- Purity
- Protein G Purified
- Packaging
- 100μg
- Price
- $717.4
- Updated
- 2021/12/16
- Product number
- orb150604
- Product name
- LRRK2 antibody
- Purity
- Protein G Purified
- Packaging
- 100μg
- Price
- $717.4
- Updated
- 2021/12/16
LRRK2 ANTIBODY Chemical Properties,Usage,Production
Source
Rabbit
Reactivity
Human;Mouse;Rat
Background
Parkinson’s disease, the second most common neurodegenerative disease after Alzheimer’s, is a progressive movement disorder characterized by rigidity, tremors, and postural instability. The pathological hallmarks of PD are progressive loss of dopaminergic neurons in the substantia nigra of the ventral midbrain and the presence of intracellular Lewy bodies in surviving neurons of the brain stem. Research studies have shown various genes and loci are genetically linked to PD including α-synuclein/PARK1 and 4, parkin/PARK2, UCH-L1/PARK5, PINK1/PARK6, DJ-1/PARK7, LRRK2/PARK8, synphilin-1, and NR4A2.Leucine-rich repeat kinase 2 contains amino-terminal leucine-rich repeats, a Ras-like small GTP binding protein-like domain, an MLK protein kinase domain, and a carboxy-terminal WD40 repeat domain. Research studies have linked at least 20 LRRK2 mutations to PD, with the G2019S mutation being the most prevalent. The G2019S mutation causes increased LRRK2 kinase activity, which induces a progressive reduction in neurite length that leads to progressive neurite loss and decreased neuronal survival. Researchers are currently testing the MLK inhibitor CEP-1347 in PD clinical trials, indicating the potential value of LRRK2 as a therapeutic target for treatment of PD.
References
[1] Fahn, S. (2003) Ann. NY Acad. Sci. 991, 1-14.
[2] Moore, D.J. et al. (2005) Annu. Rev. Neurosci. 28, 57-87.
[3] Mata, I.F. et al. (2006) Trends Neurosci. 29, 286-293.
[4] MacLeod, D. et al. (2006) Neuron 52, 587-593.
[5] Parkinson Study Group. (2004) Neurology 62, 330-332.
LRRK2 ANTIBODY Preparation Products And Raw materials
Raw materials
Preparation Products
LRRK2 ANTIBODY Suppliers
- Tel
- 18007124176 19384116026
- 2706668885@qq.com
- Country
- China
- ProdList
- 4987
- Advantage
- 58
- Tel
- 400821347
- orders@novusbio.com
- Country
- China
- ProdList
- 6434
- Advantage
- 58
- Tel
- 027-87196173
- cusabio@163.com
- Country
- China
- ProdList
- 6066
- Advantage
- 58
- Tel
- 027-19371278702 18008634902
- ruihening88@163.com
- Country
- China
- ProdList
- 3009
- Advantage
- 58
- Tel
- 0755-26755892 1-949-553-1900
- international@genetex.com
- Country
- China
- ProdList
- 6092
- Advantage
- 58
- Tel
- 858.663.9055 8586639055
- NSJBioname@qq.com
- Country
- China
- ProdList
- 6941
- Advantage
- 58
- Tel
- Enzo Biochem Inc. 13797054060
- Enzoname@qq.com
- Country
- China
- ProdList
- 6174
- Advantage
- 58
- Tel
- 21-80243558 86218024
- info@cellsignal.cn
- Country
- China
- ProdList
- 6427
- Advantage
- 58
- Tel
- 4006-123-828 13162017139
- market@ab-mart.com
- Country
- China
- ProdList
- 6917
- Advantage
- 58
- Tel
- 16615240262
- Info@leadingbiology.com
- Country
- China
- ProdList
- 6353
- Advantage
- 58